<ul>
	<li>Chloasma is occasionally seen during the use of estrogen and/or progestagen-containing preparations, especially in women with a history of chloasma gravidarum. In women with a tendency to chloasma exposure of the skin to natural or artificial sunlight may induce or aggravate the condition.</li>
	<li>Occasionally changes in parameters of liver function, carbohydrate metabolism and haemostasis may occur. If the results of relevant tests become abnormal, treatment should be discontinued. An increase in LDL-cholesterol and a decrease in HDL-cholesterol may occur during Lynestrenol therapy.</li>
	<li>During prolonged treatment with progestagens, periodic medical examinations are advisable.</li>
	<li>As determined by the effects on SHBG, lynestrenol has weak androgenic activity. This is confirmed by the slight signs of virilisation (such as acne and hirsutism) observed in some patients.</li>
	<li>Patients with any of the following conditions should be kept under close medical supervision: circulatory disorders (or a history of this condition), since with estrogen/progestagen&nbsp; containing oral contraceptive preparations a slightly increased risk of some cardiovascular disorders has been reported; some forms of severe depression,if likely to be exacerbated by sex steroid</li>
</ul>